This protocol is for patients with metabolic dysfunction-associated steatohepatitis (MASH) who also have dyslipidemia. The co-occurrence of these conditions elevates atherosclerotic cardiovascular risk, making lipid management a central treatment priority alongside hepatic considerations.
Management in this setting involves a lipid-lowering pharmacological intervention — the approach focuses on a specific class of agents targeting cholesterol reduction. The complete clinical guidance, including agent selection and therapeutic context, is detailed in the full protocol.
The primary measurable goal of this protocol is lowering of LDL-C, with the aim of reducing cardiovascular risk in patients with MASH and concurrent dyslipidemia.